MARKET WIREYahoo Finance Singapore • 14h ago
Editas Medicine, Inc. (EDIT) stock price, news, quote and historyYahoo Finance Singapore report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
Why EDIT Stock dropped -8.87% Today — RQD Quant Desk Flash
$2.67 -8.87% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $2.62
Editas Medicine Inc. (EDIT) carries a Roarable Rating of D- (Sell) with 38/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D- • RED ALERT
Cap $450.0M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on EDIT Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is EDIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Editas Medicine Inc. (NASDAQ: EDIT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.67 (-8.87% 1D, market cap $450.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EDIT ranks #578 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does EDIT compare to PROK and ALLO in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EDIT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, EDIT leads on earnings multiple (N/A) while EDIT leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for EDIT?
▼
Per EDIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650664), Editas Medicine Inc. generated $40.5M in revenue (+25.4% YoY), -$160.1M in net income, and -$165.8M in free cash flow against $186.5M in total assets and $53.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $2.62 (-1.79%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (38/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • D-
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-9% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for EDIT)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (38/100 Composite)
🔍 WHY EDIT SCORES 38/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+13/20 pts (34% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (21% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$2.75-12% Next Q
46
Q2 (-2Q)Grade D$2.42-0.8% Next Q
43
Q3 (-1Q)Grade D$2.40+11.3% Next Q
41
CurrentGrade D-$2.67-7.8% Hist 90D α
38
Trajectory: D (46) → D- (38)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a EDIT Turnaround Squeeze
While EDIT currently carries a cautious 38/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.76) and Max Pain ($2.80) forces dealer call-delta covering toward $4.14.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $EDIT• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “EDIT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why EDIT Stock dropped -8.87% Today — RQD Quant Desk Flash
Editas Medicine Inc. (EDIT) dropped -8.87% to $2.67, trading at 44% of its 52-week range ($1.66 – $3.94). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 44% of its 52-week range ($1.66 – $3.94) with RSI-14 at 57.6 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $2.67 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D- (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live EDIT Headlines & Catalysts
MARKET WIRETradingView • 17h ago
Editas Medicine, Inc. Estimates – NASDAQ:EDITTradingView report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSeeking Alpha • 20h ago
Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic ShiftSeeking Alpha report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 23h ago
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Consensus Price Target of $5.80 According to AnalystsMarketBeat report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
An experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 monthsStock Titan report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401Yahoo Finance report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst PredictionsSimply Wall St report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 1d ago
Editas wins Australia nod for gene editing trial (EDIT:NASDAQ)Seeking Alpha report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 4d ago
Global Gene Writing Technology Market Report 2026: Size, Trends, and Forecast to 2030 | Capitalize on 24.8% CAGR with Beam, Twist Bioscience, Tessera, and IntelliaKey players include Beam Therapeutics, Twist Bioscience, Sangamo, Editas Medicine and Tessera Therapeutics. Profiles cover gene-writing technologies, products, applications, trends and competition.Dublin, Oct. 29, 2026 (
MARKET WIREYahoo • 5d ago
What Would Slower New Drug Sales Do To Vertex Stock?For questions about this article or underlying research, email help@trefis.com.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring EDIT)
- ✓Walkthrough of EDIT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
EDIT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.00%▼ DESCENDING CHANNEL
2026-11-02O $2.95H $2.95L $2.67C $2.67VOL 3.23M
RES: $2.96SUP: $2.09SMA50: $2.76SMA200: $2.69
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
EDIT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +25.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on EDIT today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for EDIT. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for EDIT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (EDIT)
Health Care Rank #578 of 1016
⚔️ PROK vs EDIT Full Matrix →
1. Head-to-Head Health Care Peer Comparison (EDIT vs. PROK, ALLO, AUTL, RGNX)
Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Editas Medicine Inc. (EDIT) ranks #578 by composite RQD confidence (38/100, grade D-) and #466 by equity capitalization ($450.0M). Within this direct 5-issuer industry benchmark cohort, EDIT leads on earnings valuation at N/A trailing P/E, while EDIT leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. EDIT currently leads its immediate peer cohort in composite quantitative strength at 38/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| EDIT
ACTIVE
Editas Medicine Inc. | D- | 38/100 | — | — | -35.0% | -8.87% | $450.0M | Benchmark Subject |
| PROK ProKidney Corp. (Class A) | D- | 37/100 | — | — | -35.0% | -11.90% | $444.4M | /prok-vs-edit → |
| ALLO Allogene Therapeutics Inc. | E | 33/100 | — | — | -35.0% | -5.60% | $431.9M | /allo-vs-edit → |
| AUTL Autolus Therapeutics plc | E | 21/100 | — | -27.8% | -35.0% | -3.80% | $420.5M | /autl-vs-edit → |
| RGNX REGENXBIO Inc. | E | 27/100 | — | — | -35.0% | -2.83% | $489.2M | /rgnx-vs-edit → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001650664In its most recent audited fiscal period (FY2025, filed 2025-12-31), Editas Medicine Inc. (EDIT) reported GAAP revenue of $40.5M (+25.4% vs. FY2024 revenue of $32.3M , and -48.1% cumulative change since FY2023) , GAAP net income of -$160.1M, operating cash flow of -$165.2M, and free cash flow of -$165.8M (+24.3% YoY). On the balance sheet, EDIT closed FY2025 with $186.5M in total assets against $53.6M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $40.5M | -$160.1M | -$165.2M | -$165.8M | $186.5M | $53.6M |
| FY2024 (FY) | 2024-12-31 | $32.3M | -$237.1M | -$210.3M | -$219.1M | $341.6M | $52.4M |
| FY2023 (FY) | 2023-12-31 | $78.1M | -$153.2M | -$132.2M | -$132.2M | — | — |
3. EDIT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs EDIT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Editas Medicine Inc. (NASDAQ: EDIT) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 38/100 at a spot price of $2.67 (-8.87% 1D, market cap $450.0M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 8/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, EDIT ranks #578 in composite RQD confidence.
How does EDIT compare to PROK and ALLO in the Health Care sector?
Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), EDIT carries a Roarable D- (38/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, PROK (ProKidney Corp. (Class A)) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $444.4M) and ALLO (Allogene Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $431.9M). Among the 5-stock peer group, EDIT leads on earnings multiple (N/A) while EDIT leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for EDIT?
Per EDIT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001650664), Editas Medicine Inc. generated $40.5M in revenue (+25.4% YoY), -$160.1M in net income, and -$165.8M in free cash flow against $186.5M in total assets and $53.6M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is EDIT trading relative to its 50-day, 200-day, and 52-week technical levels?
EDIT last traded at $2.67 (-8.87% on volume of 2,909,260 shares), positioning the stock -3.26% below its 50-day simple moving average ($2.76) and -0.74% below its 200-day simple moving average ($2.69). Across its 52-week range of $1.66 to $3.94, EDIT sits at the 44.3% percentile with a 14-day RSI of 57.6 (BULLISH MOMENTUM) and an implied next-earnings move of ±12.5% ($2.34 to $3.00).
EDIT Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is EDIT stock moving today?
Why EDIT Stock dropped -8.87% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 38/100 (D-)
✓ STAGE-C NUMBER FIREWALL VERIFIED
EDIT — Editas Medicine Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:36:20Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, EDIT carries an RQD Score of 38 out of 100, a letter grade of D-, and the verdict label "Roarable Sell — Vulnerable Balance Sheet & Flow." Across the five pillars:
- Fundamental Cash Engine (6 / 20): Per the Roarable RQD rating, ROIC is -35% and FCF yield is 0%. For a prospective investor, this pillar is the weakest signal: the business is not currently generating returns on capital or free cash flow that would support valuation on cash-earnings grounds, so any upside case depends on future value creation rather than present cash generation.
- Whale / 13F Flow (13 / 20): Per the Roarable RQD rating, this pillar reflects institutional accumulation and options positioning. It is the strongest pillar in the set, indicating some institutional interest, though the underlying holder detail is not available in the source data.
- Insider Conviction (3 / 20): Per the Roarable RQD rating, this pillar reflects SEC Form 4 and Congressional PTR cluster flow and scores low. For a prospective investor, weak insider conviction is a caution flag rather than a definitive negative, since the specific trade detail is not provided.
- Macro Regime Fit (8 / 20): Per the Roarable RQD rating, beta is 1.0 with sector sensitivity noted. The stock moves in line with the broader market, offering no defensive cushion, and its exposure to sector-level sentiment is a source of volatility.
- Forensic Balance Sheet (8 / 20): Per the Roarable RQD rating, Altman Z is 2.5, Piotroski F is 3/9, and Debt/Equity is 1.96. The Piotroski score is weak and leverage relative to equity is elevated, which constrains financial flexibility.
Taken together, the score points to valuation tradeoffs: the equity is priced in the context of persistent operating losses, and the upside case rests on pipeline or strategic outcomes that the source data does not quantify. The downside risks are balance-sheet and cash-burn driven.
Business
Editas Medicine Inc. (EDIT) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the company profile, the company has a market capitalization of $0.4B. The source data does not describe its products, customers, or revenue model in detail beyond the financial figures and news headlines.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $40.5M | $-160.0M | $-160.1M | N/A | $-165.8M | $146.6M | $53.6M |
| FY 2024 | $32.3M | $-251.2M | $-237.1M | N/A | $-219.1M | $131.5M | $52.4M |
| FY 2023 | $78.1M | $-169.2M | $-153.2M | N/A | $-132.2M | N/A | N/A |
Per the SEC financials, the company reported operating losses and negative free cash flow across all three periods. Per the market data, the gross margin is 0%, the operating margin is -60%, and the net margin is -60%. Per the Roarable RQD rating, ROIC is -35% and the Altman Z-Score is 2.5, with a Piotroski F-Score of 3/9 and a Debt/Equity ratio of 1.96. Per the SEC financials, cash was $146.6M against debt of $53.6M at FY 2025, a larger cash balance than debt, though cash burn in FY 2025 exceeded the reported cash balance's annual change.
Recent Catalysts & News Wire Analysis
- Clearance of EDIT-401 trial (YELLOW, Market Wire): A headline reports shares rising after Australia cleared a Phase 1/2 trial of EDIT-401.
- Downgrade on reni-cel discontinuation (RED, Risk Watch): A Seeking Alpha item reports a downgrade to 'Hold' tied to the discontinuation of reni-cel for SCD/TDT and a strategic shift toward EDIT-401.
- Preclinical cholesterol data (YELLOW, Market Wire): A Stock Titan item reports an experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 months.
- Consensus target (YELLOW, Market Wire): A MarketBeat item reports a consensus price target of $5.80.
- Estimates and market coverage (YELLOW, Market Wire): Yahoo Finance Singapore and TradingView items cover general market action and estimates.
Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals.
Analyst View & Smart Money Ownership
Per the analyst data, no analyst records are available. Per the holders section, no holder records are available. The consensus price target of $5.80 is referenced only in the news wire headline above, not in an analyst data record. No SEC Form 4, 13F, or Congressional trade detail is provided in the source data beyond the RQD pillar scores.
Open Questions
- What are the specific product and revenue sources that generated the FY 2025 revenue of $40.5M?
- What is the timeline and cash runway implied by the FY 2025 cash balance of $146.6M against the FY 2025 free cash flow of $-165.8M?
- What insider and institutional trades underlie the insider (3 / 20) and whale-flow (13 / 20) pillar scores?
- What is the status and risk profile of the EDIT-401 program following the reported strategic shift?
- What is the basis for the reported consensus price target of $5.80, and which analysts contribute to it?
EDIT Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Editas Medicine Inc. (EDIT) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance Singapore • 14h ago
Editas Medicine, Inc. (EDIT) stock price, news, quote and history Yahoo Finance Singapore report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 17h ago
Editas Medicine, Inc. Estimates – NASDAQ:EDIT TradingView report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Seeking Alpha • 20h ago
Editas: Downgrade To 'Hold' On Reni-Cel Discontinuation SCD/TDT And EDIT-401 Strategic Shift Seeking Alpha report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 23h ago
Editas Medicine, Inc. (NASDAQ:EDIT) Stock Has Consensus Price Target of $5.80 According to Analysts MarketBeat report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
An experimental gene-editing drug kept monkeys' bad cholesterol about 90% lower for 10 months Stock Titan report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Update: Editas Medicine Shares Rise After Australia Clears Phase 1/2 Trial of EDIT-401 Yahoo Finance report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
Editas Medicine (NasdaqGS:EDIT) Stock Forecast & Analyst Predictions Simply Wall St report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 1d ago
Editas wins Australia nod for gene editing trial (EDIT:NASDAQ) Seeking Alpha report covering Editas Medicine Inc. (EDIT) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
EDIT Bull vs. Bear Conversation Board — What's Your Call at $2.67?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON EDIT 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $2.58 (-11.9%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is EDIT (D- • RQD 38/100) a Buy at $2.93?
Welcome to the EDIT (Editas Medicine Inc.) Roar Pit. Current RQD Composite is 38/100 (Roarable Sell — Vulnerable Balance Sheet & Flow) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
RI RiskArb_Desk Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $2.20 (-24.9%)
Spot @ $2.93 Pump the brakes on EDIT — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on EDIT, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Editas Medicine Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
DE DeltaGamma_99 Verified K Arena Trader 🐂 BULLISH
🎯 Target: $3.46 (+18.1%)
Spot @ $2.93 EDIT cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on EDIT, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $2.93 (52-wk range $1.66 - $3.94), any beat on forward guidance forces shorts and underweight funds to chase.